Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asparaginase erythrocyte encapsulated - PHAXIAM Therapeutics

Drug Profile

Asparaginase erythrocyte encapsulated - PHAXIAM Therapeutics

Alternative Names: ERY-001; ERY-ASP; ERYASP; Eryaspase; Erythrocyte-encapsulated L-asparaginase-PHAXIAM Therapeutics; GRASPA; L-asparaginase loaded erythrocytes-PHAXIAM Therapeutics

Latest Information Update: 28 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ERYtech Pharma
  • Developer PHAXIAM Therapeutics
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators; Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II/III Triple negative breast cancer
  • Phase II Acute myeloid leukaemia
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(First-line therapy, Metastatic disease) in Unknown (IV, Infusion)
  • 26 Jun 2023 Pherecydes Pharma has merged with ERYtech Pharma to form PHAXIAM Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top